One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (PriorixTM [MMR-RIT, GSK, Belgium]). This evidence concerns the gene ALB and rubella.